1
|
Liang W, Lu H, Sun J, Zhao G, Wang H, Guo Y, Eitzman D, Chen YE, Fan Y, Zhang J. KLF11 Protects against Venous Thrombosis via Suppressing Tissue Factor Expression. Thromb Haemost 2022; 122:777-788. [PMID: 34428834 PMCID: PMC10468287 DOI: 10.1055/s-0041-1735191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
Krüppel-like factors (KLFs) play essential roles in multiple biological functions, including maintaining vascular homeostasis. KLF11, a causative gene for maturity-onset diabetes of the young type 7, inhibits endothelial activation and protects against stroke. However, the role of KLF11 in venous thrombosis remains to be explored. Utilizing stasis-induced murine deep vein thrombosis (DVT) model and cultured endothelial cells (ECs), we identified an increase of KLF11 expression under prothrombotic conditions both in vivo and in vitro. The expression change of thrombosis-related genes was determined by utilizing gain- and loss-of-function approaches to alter KLF11 expression in ECs. Among these genes, KLF11 significantly downregulated tumor necrosis factor-α (TNF-α)-induced tissue factor (TF) gene transcription. Using reporter gene assay, chromatin immunoprecipitation assay, and co-immunoprecipitation, we revealed that KLF11 could reduce TNF-α-induced binding of early growth response 1 (EGR1) to TF gene promoter in ECs. In addition, we demonstrated that conventional Klf11 knockout mice were more susceptible to developing stasis-induced DVT. These results suggest that under prothrombotic conditions, KLF11 downregulates TF gene transcription via inhibition of EGR1 in ECs. In conclusion, KLF11 protects against venous thrombosis, constituting a potential molecular target for treating thrombosis.
Collapse
Affiliation(s)
- Wenying Liang
- Department of Internal Medicine, Frankel Cardiovascular Center, University of Michigan Medical Center, Ann Arbor, Michigan, United States
- Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, Michigan, Unites States
| | - Haocheng Lu
- Department of Internal Medicine, Frankel Cardiovascular Center, University of Michigan Medical Center, Ann Arbor, Michigan, United States
| | - Jinjian Sun
- Department of Internal Medicine, Frankel Cardiovascular Center, University of Michigan Medical Center, Ann Arbor, Michigan, United States
| | - Guizhen Zhao
- Department of Internal Medicine, Frankel Cardiovascular Center, University of Michigan Medical Center, Ann Arbor, Michigan, United States
| | - Huilun Wang
- Department of Internal Medicine, Frankel Cardiovascular Center, University of Michigan Medical Center, Ann Arbor, Michigan, United States
- Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, Michigan, Unites States
| | - Yanhong Guo
- Department of Internal Medicine, Frankel Cardiovascular Center, University of Michigan Medical Center, Ann Arbor, Michigan, United States
| | - Daniel Eitzman
- Department of Internal Medicine, Frankel Cardiovascular Center, University of Michigan Medical Center, Ann Arbor, Michigan, United States
| | - Y Eugene Chen
- Department of Internal Medicine, Frankel Cardiovascular Center, University of Michigan Medical Center, Ann Arbor, Michigan, United States
| | - Yanbo Fan
- Department of Cancer Biology, University of Cincinnati College of Medicine, Cincinnati, Ohio, Unites States
- Division of Cardiovascular Health and Disease, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, Unites States
| | - Jifeng Zhang
- Department of Internal Medicine, Frankel Cardiovascular Center, University of Michigan Medical Center, Ann Arbor, Michigan, United States
| |
Collapse
|
2
|
Venugopal J, Wang J, Mawri J, Guo C, Eitzman D. Interleukin-1 receptor inhibition reduces stroke size in a murine model of sickle cell disease. Haematologica 2021; 106:2469-2477. [PMID: 32817286 PMCID: PMC8409048 DOI: 10.3324/haematol.2020.252395] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2020] [Indexed: 12/22/2022] Open
Abstract
Sickle cell disease (SCD) is associated with chronic hemolytic anemia and a heightened inflammatory state. The causal role of inflammatory pathways in stroke associated with SCD is unclear. Therefore, the hypothesis that deletion of the non-hematopoietic interleukin-1 receptor (IL-1R) pool may be beneficial in SCD was pursued. Since potential deleterious effects of IL-1R signaling in SCD could be mediated via downstream production of interleukin-6 (IL-6), the role of the nonhematopoietic IL-6 pool was also addressed. Bone marrow transplantation (BMT) from SCD to wild-type (WT) recipient mice was used to generate SCD mice (Wt,SCDbmt). In order to generate mice with nonhematopoietic deficiency of IL-1R or IL-6, SCD marrow was transplanted into IL-1R deficient (IL1R-/-,SCDbmt) or IL-6 deficient recipients (IL6-/-, SCDbmt). Blood counts, reticulocytes, soluble E-selectin (sEsel), and IL-6 levels were analyzed 14-15 weeks post-BMT. Ischemic stroke was induced by middle cerebral artery (MCA) photothrombosis at 16 weeks post-BMT. A separate group of Wt,SCDbmt mice was given the IL-1R inhibitor, anakinra, following stroke induction. Seventy-two hours after MCA occlusion, stroke volume was assessed by staining brain sections with 2,3,5-triphenyltetrazolium chloride. Formalin-fixed brain sections were also stained for macrophages with MAC3, for endothelial activation with ICAM-1, and for loss of blood brain barrier integrity with fibrin (ogen) staining. All SCD mice generated by BMT were anemic and the severity of anemia was not different between Wt,SCDbmt, IL1R-/-,SCDbmt, and IL-6-/-,SCDbmt mice. Three days following MCA occlusion, stroke volume was significantly reduced in IL1R-/-,SCDbmt mice compared to Wt,SCDbmt mice and IL6-/-,SCDbmt mice. Plasma levels of sEsel were lower in IL1R-/-,SCDbmt compared to Wt,SCDbmt and IL-6-/-,SCDbmt mice. Post-stroke treatment of Wt,SCDbmt mice with anakinra decreased stroke size, leukocyte infiltration, ICAM-1 expression, and fibrin(ogen) accumulation compared to vehicle-treated mice. Deficiency of non-hematopoietic IL-1R or treatment with an IL-1R antagonist is sufficient to confer protection against the increased stroke size associated with SCD. These effects of IL1R deficiency are associated with reduced endothelial activation, leukocyte infiltration, and blood brain barrier disruption, and are independent of non-hematopoietic IL-6 signaling.
Collapse
Affiliation(s)
- Jessica Venugopal
- University of Michigan Internal Medicine - Cardiology division, Ann Arbor, MI, USA
| | - Jintao Wang
- University of Michigan Internal Medicine - Cardiology division, Ann Arbor, MI, USA
| | | | - Chiao Guo
- University of Michigan Internal Medicine - Cardiology division, Ann Arbor, MI, USA
| | - Daniel Eitzman
- University of Michigan Internal Medicine - Cardiology division, Ann Arbor, MI, USA
| |
Collapse
|
4
|
Liang W, Fan Y, Lu H, Chang Z, Hu W, Sun J, Wang H, Zhu T, Wang J, Adili R, Garcia-Barrio MT, Holinstat M, Eitzman D, Zhang J, Chen YE. KLF11 (Krüppel-Like Factor 11) Inhibits Arterial Thrombosis via Suppression of Tissue Factor in the Vascular Wall. Arterioscler Thromb Vasc Biol 2020; 39:402-412. [PMID: 30602303 DOI: 10.1161/atvbaha.118.311612] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
Objective- Mutations in Krüppel like factor-11 ( KLF11), a gene also known as maturity-onset diabetes mellitus of the young type 7, contribute to the development of diabetes mellitus. KLF11 has anti-inflammatory effects in endothelial cells and beneficial effects on stroke. However, the function of KLF11 in the cardiovascular system is not fully unraveled. In this study, we investigated the role of KLF11 in vascular smooth muscle cell biology and arterial thrombosis. Approach and Results- Using a ferric chloride-induced thrombosis model, we found that the occlusion time was significantly reduced in conventional Klf11 knockout mice, whereas bone marrow transplantation could not rescue this phenotype, suggesting that vascular KLF11 is critical for inhibition of arterial thrombosis. We further demonstrated that vascular smooth muscle cell-specific Klf11 knockout mice also exhibited significantly reduced occlusion time. The expression of tissue factor (encoded by the F3 gene), a main initiator of the coagulation cascade, was increased in the artery of Klf11 knockout mice, as determined by real-time quantitative polymerase chain reaction and immunofluorescence. Furthermore, vascular smooth muscle cells isolated from Klf11 knockout mouse aortas showed increased tissue factor expression, which was rescued by KLF11 overexpression. In human aortic smooth muscle cells, small interfering RNA-mediated knockdown of KLF11 increased tissue factor expression. Consistent results were observed on adenovirus-mediated overexpression of KLF11. Mechanistically, KLF11 downregulates F3 at the transcriptional level as determined by reporter and chromatin immunoprecipitation assays. Conclusions- Our data demonstrate that KLF11 is a novel transcriptional suppressor of F3 in vascular smooth muscle cells, constituting a potential molecular target for inhibition of arterial thrombosis.
Collapse
Affiliation(s)
- Wenying Liang
- From the Department of Internal Medicine, Cardiovascular Center, University of Michigan Medical Center, Ann Arbor (W.L., Y.F., H.L., Z.C., W.H., J.S., H.W., T.Z., J.W., M.T.G.-B., D.E., J.Z., Y.E.C.)
| | - Yanbo Fan
- From the Department of Internal Medicine, Cardiovascular Center, University of Michigan Medical Center, Ann Arbor (W.L., Y.F., H.L., Z.C., W.H., J.S., H.W., T.Z., J.W., M.T.G.-B., D.E., J.Z., Y.E.C.)
| | - Haocheng Lu
- From the Department of Internal Medicine, Cardiovascular Center, University of Michigan Medical Center, Ann Arbor (W.L., Y.F., H.L., Z.C., W.H., J.S., H.W., T.Z., J.W., M.T.G.-B., D.E., J.Z., Y.E.C.)
| | - Ziyi Chang
- From the Department of Internal Medicine, Cardiovascular Center, University of Michigan Medical Center, Ann Arbor (W.L., Y.F., H.L., Z.C., W.H., J.S., H.W., T.Z., J.W., M.T.G.-B., D.E., J.Z., Y.E.C.)
| | - Wenting Hu
- From the Department of Internal Medicine, Cardiovascular Center, University of Michigan Medical Center, Ann Arbor (W.L., Y.F., H.L., Z.C., W.H., J.S., H.W., T.Z., J.W., M.T.G.-B., D.E., J.Z., Y.E.C.)
| | - Jinjian Sun
- From the Department of Internal Medicine, Cardiovascular Center, University of Michigan Medical Center, Ann Arbor (W.L., Y.F., H.L., Z.C., W.H., J.S., H.W., T.Z., J.W., M.T.G.-B., D.E., J.Z., Y.E.C.)
| | - Huilun Wang
- From the Department of Internal Medicine, Cardiovascular Center, University of Michigan Medical Center, Ann Arbor (W.L., Y.F., H.L., Z.C., W.H., J.S., H.W., T.Z., J.W., M.T.G.-B., D.E., J.Z., Y.E.C.)
| | - Tianqing Zhu
- From the Department of Internal Medicine, Cardiovascular Center, University of Michigan Medical Center, Ann Arbor (W.L., Y.F., H.L., Z.C., W.H., J.S., H.W., T.Z., J.W., M.T.G.-B., D.E., J.Z., Y.E.C.)
| | - Jintao Wang
- From the Department of Internal Medicine, Cardiovascular Center, University of Michigan Medical Center, Ann Arbor (W.L., Y.F., H.L., Z.C., W.H., J.S., H.W., T.Z., J.W., M.T.G.-B., D.E., J.Z., Y.E.C.)
| | - Reheman Adili
- Department of Pharmacology, University of Michigan, Ann Arbor (R.A., M.H.)
| | - Minerva T Garcia-Barrio
- From the Department of Internal Medicine, Cardiovascular Center, University of Michigan Medical Center, Ann Arbor (W.L., Y.F., H.L., Z.C., W.H., J.S., H.W., T.Z., J.W., M.T.G.-B., D.E., J.Z., Y.E.C.)
| | - Michael Holinstat
- Department of Pharmacology, University of Michigan, Ann Arbor (R.A., M.H.)
| | - Daniel Eitzman
- From the Department of Internal Medicine, Cardiovascular Center, University of Michigan Medical Center, Ann Arbor (W.L., Y.F., H.L., Z.C., W.H., J.S., H.W., T.Z., J.W., M.T.G.-B., D.E., J.Z., Y.E.C.)
| | - Jifeng Zhang
- From the Department of Internal Medicine, Cardiovascular Center, University of Michigan Medical Center, Ann Arbor (W.L., Y.F., H.L., Z.C., W.H., J.S., H.W., T.Z., J.W., M.T.G.-B., D.E., J.Z., Y.E.C.)
| | - Y Eugene Chen
- From the Department of Internal Medicine, Cardiovascular Center, University of Michigan Medical Center, Ann Arbor (W.L., Y.F., H.L., Z.C., W.H., J.S., H.W., T.Z., J.W., M.T.G.-B., D.E., J.Z., Y.E.C.)
| |
Collapse
|